Organon & Co. Common Stock vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $42 (market cap $3.80B). The key difference: Organon & Co. Common Stock and Vanguard Global ex-US Real Estate Index Fd ETF are close in size by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Vanguard Global ex-US Real Estate Index Fd ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Vanguard Global ex-US Real Estate Index Fd ETF for 96 Days on average.
| OGN | VNQI | |
|---|---|---|
Market Cap | $3.61B | $3.80B |
Volume | 1,808,049 | 216,754 |
Sector | Health | — |
52-Week High | $13.81 | $50.76 |
52-Week Low | $5.70 | $41.81 |
Typical Hold Time | 0 Days | 96 Days |
Enterprise Value | $11.03B | — |
Dividend Yield | 0.58% | — |
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →